Tidal Investments LLC Sells 8,930 Shares of DexCom, Inc. (NASDAQ:DXCM)

Tidal Investments LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 24.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,812 shares of the medical device company's stock after selling 8,930 shares during the period. Tidal Investments LLC's holdings in DexCom were worth $2,163,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of DXCM. Merit Financial Group LLC acquired a new position in shares of DexCom during the fourth quarter valued at about $228,000. UMB Bank n.a. lifted its stake in shares of DexCom by 82.4% in the 4th quarter. UMB Bank n.a. now owns 1,678 shares of the medical device company's stock valued at $130,000 after purchasing an additional 758 shares during the period. MassMutual Private Wealth & Trust FSB boosted its stake in shares of DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock worth $65,000 after acquiring an additional 265 shares in the last quarter. Ballentine Partners LLC purchased a new position in shares of DexCom during the 4th quarter valued at approximately $215,000. Finally, Atomi Financial Group Inc. raised its position in shares of DexCom by 36.5% during the 4th quarter. Atomi Financial Group Inc. now owns 5,374 shares of the medical device company's stock worth $418,000 after purchasing an additional 1,438 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on DXCM shares. Canaccord Genuity Group boosted their price objective on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Robert W. Baird decreased their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Barclays lifted their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $98.00.

Insider Activity

In other DexCom news, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. The trade was a 4.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This trade represents a 10.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,926 shares of company stock worth $4,734,384 in the last 90 days. Corporate insiders own 0.32% of the company's stock.

DexCom Price Performance

DXCM stock traded up $0.88 during trading on Tuesday, hitting $85.39. 1,064,827 shares of the stock traded hands, compared to its average volume of 4,359,119. The stock has a market cap of $33.48 billion, a price-to-earnings ratio of 59.73, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a one year low of $57.52 and a one year high of $128.63. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a 50 day simple moving average of $73.76 and a 200 day simple moving average of $78.36.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.32 EPS. Equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.